Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2019 | Story Valentino Ndaba | Photo Rulanzen Martin
Dr Thuli Mphambukeli and Victor Okorie
Water is a fundamental human right, says Dr Thulisile Mphambukeli, (left) Senior Lecturer at the Department of Urban and Regional Planning. On the right is Dr Victor Okorie.

Research shows that “access to water and food remains critical to the survival and stability of any nation”. This is according to a team of academics that has been hard at work exploring ways in which to secure water and food in Brazil, Russia, India, China and South Africa (BRICS nations).

These scholars from the University of the Free State (UFS) and North-West University recently published a paper titled: Exploring the Political Economy of Water and Food Security Nexus in BRICS. Dr Thulisile Mphambukeli, Dr Victor Okorie, and Prof Samuel Amusan are members of the Food Security Research Cluster of the South African BRICS Think Tank that has been fervently tackling the water and food in(security) challenge.

Water as a key to social justice 

The team argues that unequal access and distribution of water has in the past led to violent conflict. The paper cites Qwaqwa as one of the many areas affected by water-service protests in the recent past. “Water and food crises are worsening thanks to the intensification of climate change, rapid urbanisation, nutrition transition and population growth. Solutions to these crises partly lie in cooperation and collaboration among nation states, regional economic commissions, and global power brokers.”

What are some of the local solutions? According to the scholars: “For agronomic and husbandry practices, there is a pressing need for research activities on innovative ways of supplying water to crops and animals such that water loss through evaporation and run-off is significantly reduced. 

“Similarly, research activities on redesigning toilets, especially the urinary section – where more than nine litres of water are used to flush less than one cubic centimetre of urine – are timely in the context of managing the water and food security nexus crises.”

Improving livelihoods

In an effort to achieve food security, BRICS aims to stimulate domestic capacity for production. Food and nutrition security cannot be achieved without water security, and vice versa. 

It is evident that the water and food insecurity issues are complex. However, concerted efforts are being made by various sectors to solve these challenges and improve the livelihoods of urban and rural citizens within BRICS nations.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept